Trial site
Noyes Memorial Hospital/Myers Cancer Center
Dansville, New York 14437, United StatesNot linked to an institution yet
The trials here
What the 11 trials at this site are about, from their registry records.
- Phase
- Phase 37 trials
- Phase 2/32 trials
- Phase 21 trial
- Status
- Active, not recruiting5 trials
- Recruiting5 trials
- Suspended1 trial
- Lead sponsor
- NRG Oncology6 trials
- National Cancer Institute (NCI)2 trials
- ECOG-ACRIN Cancer Research Group1 trial
- SWOG Cancer Research Network1 trial
- University of Rochester1 trial
Running trials
Recruiting
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin
NCT07441681· Phase 3· NRG Oncology· Source
Contact: Randall J. Kimple (principal investigator)
Recruiting
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NCT05946213· Phase 3· NRG Oncology· Source
Contact: Kevin C. Bylund (principal investigator)
Recruiting
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
NCT06073431· University of Rochester· Source
Contact: Po-Ju Lin (principal investigator)
Recruiting
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
NCT05624996· Phase 3· NRG Oncology· Source
Contact: Deepinder P. Singh (principal investigator)
Active, not recruiting
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NCT05095376· Phase 3· NRG Oncology· Source
Active, not recruiting
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NCT05050084· Phase 3· NRG Oncology· Source
Active, not recruiting
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NCT04513717· Phase 3· NRG Oncology· Source
Active, not recruiting
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
NCT04166318· Phase 2· ECOG-ACRIN Cancer Research Group· Source
Active, not recruiting
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
NCT03952585· Phase 2/3· National Cancer Institute (NCI)· Source
Recruiting
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
NCT03678025· Phase 3· SWOG Cancer Research Network· Source
Contact: Paul M. Barr (principal investigator)
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error